Thursday May 25th 2017

Why MS sufferers like me need the highs and lows of unrealistic optimism | Peter Thompson

Statins may not be the miracle cure we keep looking for. But, just as when I was diagnosed, I believe science will be my salvationAnother day, another bit of exciting news about a medical breakthrough. For a multiple sclerosis patient like me, the course of a day can see you raised from a height of happiness and expectation at a headline to a low brought on by qualification and small print. In some ways, the greatest breakthrough would be a pill that protects one against those highs and lows. Meanwhile one has to fall back on an ability to read between the lines, differentiate journalistic hyperbole from medical realism, and come to a conclusion that allows for hope but prepares for disappointment.Today’s news is that certain statins, taken in high dose, may help to slow down the progress …

Read the article:  

Why MS sufferers like me need the highs and lows of unrealistic optimism | Peter Thompson

Leave a Comment

More from category

MS Study Alert: Share Your Thoughts About MS Research
MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS
First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows
Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint
Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]